Bortezomib in combination with celecoxib in patients with advanced solid tumors: A phase I trial

BMC Cancer

Volumn 7, Issue , 2007, Pages

  Hayslip, John ^a   Chaudhary, Uzair ^a   Green, Mark ^a   Meyer, Mario ^a   Dunder, Steven ^a   Sherman, Carol ^a   Salzer, Shanta ^a   Kraft, Andrew ^a   Montero, Alberto J ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CELECOXIB; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ADRENAL CORTEX CARCINOMA; ADULT; AGED; ANEMIA; ARTICLE; CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; DOWN REGULATION; DRUG DOSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG TOXICITY; DRUG WITHDRAWAL; EDEMA; ESOPHAGUS CANCER; FATIGUE; FEMALE; HISTOLOGY; HUMAN; HYPERKALEMIA; HYPOALBUMINEMIA; INFECTION; INSOMNIA; KIDNEY CANCER; LEIOMYOSARCOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEOPLASM; NEUROPATHY; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRURITUS; RADIOTHERAPY; SIDE EFFECT; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TRANSITIONAL CELL CARCINOMA; TUMOR GROWTH; UTERINE TUBE CARCINOMA; WEAKNESS; COHORT ANALYSIS; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PYRAZINES; PYRAZOLES; SULFONAMIDES;

EID: 39049096264     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-7-221     Document Type: Article

References (33)

1. Nandi D Tahiliani P Kumar A Chandu D The ubiquitin-proteasome system J Biosci 2006, 31(1):137-155. 10.1007/BF02705243 16595883
2. Ciechanover A Iwai K The ubiquitin system: From basic mechanisms to the patient bed IUBMB Life 2004, 56(4):193-201. 15230346
3. Lowe SW Schmitt EM Smith SW Osborne BA Jacks T p53 is required for radiation-induced apoptosis in mouse thymocytes Nature 1993, 362(6423):847-849. 10.1038/362847a0 8479522
4. King RW Deshaies RJ Peters JM Kirschner MW How proteolysis drives the cell cycle Science 1996, 274(5293):1652-1659. 10.1126/ science.274.5293.1652 8939846
5. Read MA Neish AS Luscinskas FW Palombella VJ Maniatis T Collins T The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression Immunity 1995, 2(5):493-506. 10.1016/1074-7613(95)90030-6 7538441
6. Thun MJ Namboodiri MM Calle EE Flanders WD Heath CW Jr. Aspirin use and risk of fatal cancer Cancer Res 1993, 53(6)1322-1327. 8443812
7. Funkhouser EM Sharp GB Aspirin and reduced risk of esophageal carcinoma Cancer 1995, 76(7):1116-1119. 10.1002/ 1097-0142(19951001)76:7<1116::AID-CNCR2820760703<3.0.CO;2-I 8630885
8. Coogan PF Rosenberg L Palmer JR Strom BL Zauber AG Stolley PD Shapiro S Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel Cancer Epidemiol Biomarkers Prev 2000, 9(1):119-123. 10667472
9. Jung TT Berlinger NT Juhn SK Prostaglandins in squamous cell carcinoma of the head and neck: A preliminary study Laryngoscope 1985, 95(3):307-312. 10.1288/00005537-198503000-00014 3919231
10. Castonguay A Rioux N Inhibition of lung tumourigenesis by sulindac: comparison of two experimental protocols Carcinogenesis 1997, 18(3):491-496. 10.1093/carcin/18.3.491 9067547
11. Harris RE Alshafie GA Abou-Issa H Seibert K Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor Cancer research 2000, 60(8):2101-2103. 10786667
12. Harris RE Namboodiri KK Farrar WB Nonsteroidal antiinflammatory drugs and breast cancer Epidemiology (Cambridge, Mass 1996, 7(2):203-205. 8834563
13. McCormick DL Moon RC Inhibition of mammary carcinogenesis by flurbiprofen, a non-steroidal antiinflammatory agent Br J Cancer 1983, 48(6):859-861. 6652027
14. Giovannucci E Rimm EB Stampfer MJ Colditz GA Ascherio A Willett WC Aspirin use and the risk for colorectal cancer and adenoma in male health professionals Ann Intern Med 1994, 121(4):241-246. 8037405
15. Giardiello FM Hamilton SR Krush AJ Piantadosi S Hylind LM Celano P Booker SV Robinson CR Offerhaus GJ Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis N Engl J Med 1993, 328(18):1313-1316. 10.1056/NEJM199305063281805 8385741
16. Boolbol SK Dannenberg AJ Chadburn A Martucci C Guo XJ Ramonetti JT Abreu-Goris M Newmark HL Lipkin ML DeCosse JJ Bertagnolli MM Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis Cancer Res 1996, 56(11):2556-2560. 8653697
17. Sano H Kawahito Y Wilder RL Hashiramoto A Mukai S Asai K Kimura S Kato H Kondo M Hla T Expression of cyclooxygenase-1 and -2 in human colorectal cancer Cancer Res 1995, 55(17):3785-3789. 7641194
18. Tsujii M Kawano S Tsuji S Sawaoka H Hori M DuBois RN Cyclooxygenase regulates angiogenesis induced by colon cancer cells Cell 1998, 93(5):705-716. 10.1016/S0092-8674(00)81433-6 9630216
19. Leahy KM Koki AT Masferrer JL Role of cyclooxygenases in angiogenesis Curr Med Chem 2000, 7(11):1163-1170. 11032965
20. Takada Y Bhardwaj A Potdar P Aggarwal BB Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation Oncogene 2004, 23(57):9247-9258. 15489888
21. Ma MH Yang HH Parker K Manyak S Friedman JM Altamirano C Wu ZQ Borad MJ Frantzen M Roussos E Neeser J Mikail A Adams J Sjak-Shie N Vescio RA Berenson JR The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents Clin Cancer Res 2003, 9(3):1136-1144. 12631619
22. Minami T Adachi M Kawamura R Zhang Y Shinomura Y Imai K Sulindac enhances the proteasome inhibitor bortezomib-mediated oxidative stress and anticancer activity Clin Cancer Res 2005, 11(14):5248- 5256. 10.1158/ 1078-0432.CCR-05-0085 16033843
23. Kim SH Song SH Kim SG Chun KS Lim SY Na HK Kim JW Surh YJ Bang YJ Song YS Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-kappaB as a possible target Journal of cancer research and clinical oncology 2004, 130(9):551-560. 10.1007/ s00432-004-0567-6
24. Aghajanian C Soignet S Dizon DS Pien CS Adams J Elliott PJ Sabbatini P Miller V Hensley ML Pezzulli S Canales C Daud A Spriggs DR A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies Clin Cancer Res 2002, 8(8):2505-2511. 12171876
25. Papandreou CN Daliani DD Nix D Yang H Madden T Wang X Pien CS Millikan RE Tu SM Pagliaro L Kim J Adams J Elliott P Esseltine D Petrusich A Dieringer P Perez C Logothetis CJ Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer J Clin Oncol 2004, 22(11):2108-2121. 10.1200/JCO.2004.02.106 15169797
26. Solomon SD McMurray JJ Pfeffer MA Wittes J Fowler R Finn P Anderson WF Zauber A Hawk E Bertagnolli M Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention N Engl J Med 2005, 352(11):1071-1080. 10.1056/NEJMoa050405 15713944
27. Therasse P Arbuck SG Eisenhauer EA Wanders J Kaplan RS Rubinstein L Verweij J Van Glabbeke M van Oosterom AT Christian MC Gwyther SG New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 2000, 92(3):205-216. 10.1093/jnci/92.3.205 10655437
28. Pruthi RS Derksen JE Moore D Carson CC Grigson G Watkins C Wallen E Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy Clin Cancer Res 2006, 12(7 Pt 1):2172-2177. 10.1158/ 1078-0432.CCR-05-2067 16609031
29. Fanucchi MP Fossella FV Belt R Natale R Fidias P Carbone DP Govindan R Raez LE Robert F Ribeiro M Akerley W Kelly K Limentani SA Crawford J Reimers HJ Axelrod R Kashala O Sheng S Schiller JH Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer J Clin Oncol 2006, 24(31):5025-5033. 10.1200/JCO.2006.06.1853 17075122
30. Kondagunta GV Drucker B Schwartz L Bacik J Marion S Russo P Mazumdar M Motzer RJ Phase II trial of bortezomib for patients with advanced renal cell carcinoma J Clin Oncol 2004, 22(18):3720-3725. 10.1200/ JCO.2004.10.155 15365068
31. Markovic SN Geyer SM Dawkins F Sharfman W Albertini M Maples W Fracasso PM Fitch T Lorusso P Adjei AA Erlichman C A phase II study of bortezomib in the treatment of metastatic malignant melanoma Cancer 2005, 103(12):2584-2589. 10.1002/cncr.21108 15887220
32. Mackay H Hedley D Major P Townsley C Mackenzie M Vincent M Degendorfer P Tsao MS Nicklee T Birle D Wright J Siu L Moore M Oza A A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer Clin Cancer Res 2005, 11(15):5526-5533. 10.1158/1078-0432.CCR-05-0081 16061869
33. Yang CH Gonzalez-Angulo AM Reuben JM Booser DJ Pusztai L Krishnamurthy S Esseltine D Stec J Broglio KR Islam R Hortobagyi GN Cristofanilli M Bortezomib (VELCADE) in metastatic breast cancer: Pharmacodynamics, biological effects, and prediction of clinical benefits Ann Oncol 2006, 17(5):813-817. 10.1093/annonc/mdj131 16403809